论文部分内容阅读
目的探讨泮托拉唑联合生长抑素治疗肝硬化患者上消化道出血临床疗效。方法将河南省人民医院2015年6月—2016年12月收治的84例确诊为肝硬化并发上消化道出血的患者随机分为两组,对照组、治疗组各42例,两组患者均给予禁食、补液、保肝、抗感染等基础治疗,治疗组给予泮托拉唑联合生长抑素,对照组给予奥美拉唑联合生长抑素,观察两组患者的止血时间、止血成功率及不良反应。结果治疗组止血时间为(20.17±6.32),与对照组(21.26±7.56)相比较,P>0.05,无统计学意义;治疗组总有效率为88.10%,对照组总有效率85.71%,二者比较,差异无统计学意义(P>0.05);不良反应发生率治疗组4例,对照组5例,二者比较,差异无统计学意义(P>0.05)。结论泮托拉唑联合生长抑素治疗肝硬化患者上消化道大出血与奥美拉唑联合生长抑素治疗肝硬化患者上消化道大出血临床疗效无明显差异。
Objective To investigate the clinical efficacy of pantoprazole and somatostatin in the treatment of upper gastrointestinal bleeding in patients with liver cirrhosis. Methods Eighty-four patients with cirrhosis complicated with upper gastrointestinal hemorrhage admitted to Henan Provincial People’s Hospital from June 2015 to December 2016 were randomly divided into two groups, 42 cases in control group and 42 cases in treatment group, Fasting, rehydration, liver protection, anti-infective and other basic treatment, the treatment group was given pantoprazole combined with somatostatin, the control group was given omeprazole combined with somatostatin, the two groups were observed bleeding time, hemostasis success rate Adverse reactions. Results The bleeding time in the treatment group was (20.17 ± 6.32), compared with that in the control group (21.26 ± 7.56), P> 0.05, but the total effective rate was 88.10% in the treatment group and 85.71% in the control group. There was no significant difference between the two groups (P> 0.05). The incidence of adverse reactions was 4 cases in the treatment group and 5 cases in the control group. There was no significant difference between the two groups (P> 0.05). Conclusion The combination of pantoprazole and somatostatin in patients with cirrhosis of upper gastrointestinal bleeding and omeprazole combined with somatostatin in patients with cirrhosis of upper gastrointestinal bleeding no significant difference in clinical efficacy.